PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology

Pmv Pharmaceuticals, Inc. (PMVP) announced an update on their ongoing clinical study.

The phase 1 study, officially titled “A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation,” aims to test how PMV Pharmaceuticals, Inc.’s rezatapopt interacts with common medicines. It targets patients with advanced tumors that have a specific TP53 Y220C mutation and helps define how usable the drug could be in real cancer care.

The main treatment is rezatapopt, an oral cancer drug candidate designed to target tumors with the TP53 Y220C mutation. The study also uses four approved drugs, metformin, rosuvastatin, repaglinide, and midazolam, as a “cocktail” to see how rezatapopt may change their levels in the body.

This is an interventional phase 1 trial with a single experimental arm where patients act as their own controls in a sequential design. The study is open-label with no masking, and the main goal is treatment focused, checking both safety and how rezatapopt affects the handling of other drugs.

Part A runs over 24 days and measures drug levels before and after rezatapopt is added, while Part B gives rezatapopt alone in 21-day cycles for up to 33 cycles. This setup lets the sponsor track short-term drug interactions and longer-term treatment exposure, which is key for later phase studies and possible real-world use.

The study was first submitted on January 5, 2026, marking the formal start of regulatory tracking for this program. The latest update was submitted on March 10, 2026, confirming that the trial record is active and that the recruiting status remains current.

The trial is listed as recruiting, so primary completion and final completion dates are still in the future and not yet posted. These future dates will matter for investors, since readouts from this study can shape the path to broader rezatapopt trials and inform timelines for potential approvals.

For PMV Pharmaceuticals (PMVP), this update signals continued execution of its precision oncology strategy focused on TP53-mutant cancers. Positive data on drug interactions would support rezatapopt’s use alongside common chronic medicines, which could expand its real-world market and reduce future safety overhangs in the stock.

Investor sentiment in small-cap biotech often moves on signs of steady pipeline progress rather than only late-stage results. Within the targeted oncology space, where peers also chase specific mutations, clear safety and interaction data can be a differentiator and may support PMVP’s valuation versus similar early-stage competitors.

At this stage, the study does not yet provide efficacy data, so any stock impact is more about de-risking and confidence in development rather than near-term revenue. Still, ongoing recruiting and timely updates help lower perceived execution risk, which can support trading levels in advance of future, more decisive readouts.

The study is currently ongoing and recently updated, with further details available on the ClinicalTrials portal.

To learn more about PMVP’s potential, visit the Pmv Pharmaceuticals, Inc. drug pipeline page.